C
Clemens M. Wendtner
Researcher at Ludwig Maximilian University of Munich
Publications - 118
Citations - 16544
Clemens M. Wendtner is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Chronic lymphocytic leukemia & Fludarabine. The author has an hindex of 37, co-authored 106 publications receiving 13614 citations. Previous affiliations of Clemens M. Wendtner include University of Calgary & University of Bonn.
Papers
More filters
Journal ArticleDOI
Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG4 Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme.
Alessandro M. Gianni,Carmelo Carlo-Stella,Anna Guidetti,Michael Hallek,Carmen D. Schweighofer,Clemens M. Wendtner,Michele Ghielmini,Erica Lerch,Sabine Sperka,Douglas Greene,Oliver Krieter,Faith E. Nathan,Michael E. Petrone +12 more
TL;DR: Preliminary data suggest that 1D09C3 is well tolerated within this heavily pre-treated patient population and may offer a novel therapy to patients with B-cell lymphoma who have failed therapy.
Journal ArticleDOI
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study
Thomas Wimmer,Raphael Mattes,Hans-Joachim Stemmler,Fabian Hauck,Hendrik Schulze-Koops,Stephanie-S. Stecher,Michael Starck,Clemens M. Wendtner,Peter Bojko,Marcus Hentrich,Katharina E Nickel,Katharina Götze,Florian Bassermann,Michael von Bergwelt-Baildon,Karsten Spiekermann +14 more
TL;DR: SCD25 could be a useful marker for the prognosis of patients with HLH that might help to stratify therapeutic interventions, and in multivariate analysis sCD25 remained the only significant prognostic factor.
Journal ArticleDOI
P641: retreatment with venetoclax after venetoclax, obinutuzumab +/- ibrutinib: pooled analysis of 13 patients with chronic lymphocytic leukemia (cll) treated in gcllsg trials
Paula Cramer,Moritz Fürstenau,Adam Giza,Sandra Robrecht,Eugen Tausch,Christof W. Schneider,Clemens M. Wendtner,Manuela Hoechstetter,Johannes Schetelig,Sebastian Böttcher,Peter Dreger,A.-M. Fink,Petra Langerbeins,Othman Al-Sawaf,Kirsten Fischer,Stephan Stilgenbauer,B.F Eichhorst,Michael Hallek +17 more
TL;DR: In this article , the authors pooled the patients with two consecutive V-containing treatment lines from GCLLSG trials, to study efficacy and safety of a re-treatment with V-based regimens.
Journal ArticleDOI
Health-Related Quality of Life Impairment in Patients with Chronic Myeloid Leukemia: Results of a German Cross-Sectional Study of Patients Registered in Prospective, Controlled Clinical Trials
Susanne Saussele,Mareike Stein,Arthur Gil,Ute Kossak-Roth,Michael Lauseker,Ulrike Proetel,Hermann Einsele,Philippe Schafhausen,Elisabeth Lange,Mathias Hänel,Karsten Spiekermann,Martin Sökler,Clemens M. Wendtner,Stephan Kremers,Michael Pfreundschuh,Ernst Holler,Wolf-Karsten Hofmann,Andreas Hochhaus,Martin C. Müller,Ruediger Hehlmann,Markus Pfirrmann +20 more
TL;DR: In this cross-sectional study, women showed an impaired global health status, role, emotional, and physical functioning compared to males, and the HRQoL was significantly impaired in all scales when compared to the German population.
Journal ArticleDOI
Increased Functional T Cell Defects in Patients with low CD4 Counts after Allogeneic Hematopoietic Stem Cell Transplantation
Udo Holtick,Lukas P. Frenzel,Shimabukuro-Vornhagen Alexander,Sebastian Theurich,Julia Claasen,Christof Scheid,Michael von-Bergwelt-Baildon,Michael Hallek,Clemens M. Wendtner,Jens Chemnitz +9 more
TL;DR: The severity of the CD4 numerical defect reflects the state of immunosuppression as demonstrated by RNA immuno-inhibitory fingerprint motives and should be considered for the decision to stop or maintain anti-microbial prophylaxis in patients after allogeneic stem cell transplantation.